← Company Index
Pharma & CDMOKOSPI 0126Z030 approvals

SAMSUNG EPIS HOLDINGS Co., Ltd.

Official website

Founded and KOSPI-listed in November 2025, Samsung Epis Holdings is a biotech holding company led by subsidiary Samsung Bioepis.

As of 2026-11-21, SAMSUNG EPIS HOLDINGS Co., Ltd. has 20 Korean MFDS drug approvals, 10 US FDA clearances/approvals, 119 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in November 2025 and listed on KOSPI the same month, Samsung Epis Holdings is a biotech investment holding company with two subsidiaries, Samsung Bioepis and Epis NexLab. Through Samsung Bioepis, it has globally commercialized 11 biosimilars referencing Remicade, Herceptin, Enbrel, Humira, Avastin, Lucentis, Soliris, Eylea, Stelara, Prolia, and Xgeva. In 2025, biosimilar product sales accounted for KRW 247.5 billion (98.3%) of revenue, with other service revenue of KRW 4.2 billion (3.3%).

Products & technology

  • Remicade biosimilar
  • Herceptin biosimilar
  • Enbrel biosimilar
  • Humira biosimilar
  • Avastin biosimilar
  • Lucentis biosimilar
  • Soliris biosimilar
  • Eylea biosimilar
  • Stelara biosimilar (SB17)
  • Prolia biosimilar (SB16)
  • Xgeva biosimilar (SB16)

Regulatory approvals

data.go.kr · openFDA

20 Korean MFDS drug approvals · 2015–2026 / 10 US FDA drug approvals · 2017–2025

  • MFDS drugSubsidiary: 삼성바이오에피스(주)Epyztek Pre-filled pen2026-01-13
    Drug · Prescription · Approval202600119
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Xbryk 120 mg solution for injection2025-05-30
    Drug · Prescription · Approval202501346
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Obodence 60 mg solution for injection in pre-filled syringe2025-04-04
    Drug · Prescription · Approval202500817
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Afilivu Pre-filled Syringe (Aflibercept)2025-03-13
    Drug · Prescription · Approval202500560
  • FDA drugSubsidiary: 삼성바이오에피스(주)DENOSUMAB-DSSB2025-02-13
    FDA drug approval · BLABLA761392
  • MFDS drugSubsidiary: 삼성바이오에피스(주)AMELIVU PFS2024-11-04
    Drug · Prescription · Approval202402591
  • FDA drugSubsidiary: 삼성바이오에피스(주)EPYSQLI2024-07-19
    FDA drug approval · BLABLA761340
  • FDA drugSubsidiary: 삼성바이오에피스(주)PYZCHIVA2024-06-28
    FDA drug approval · BLABLA761373
  • FDA drugSubsidiary: 삼성바이오에피스(주)PYZCHIVA2024-06-28
    FDA drug approval · BLABLA761425
  • FDA drugSubsidiary: 삼성바이오에피스(주)OPUVIZ2024-05-20
    FDA drug approval · BLABLA761350
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Epyztek IV injection2024-04-11
    Drug · Prescription · Approval202400826
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Epyztek Pre-filled syringe2024-04-11
    Drug · Prescription · Approval202400827
Show 18 more
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Afilivu Injection (Aflibercept)2024-02-23
    Drug · Prescription · Approval202400392
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Epysqli2024-01-19
    Drug · Prescription · Approval202400147
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Adalloce 40 mg/0.4 mL solution for injection in pre-filled pen2023-01-03
    Drug · Prescription · Approval202300028
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Adalloce 40 mg/0.4 mL solution for injection in pre-filled syringe2023-01-03
    Drug · Prescription · Approval202300029
  • MFDS drugSubsidiary: 삼성바이오에피스(주)AMELIVU2022-05-13
    Drug · Prescription · Approval202202008
  • FDA drugSubsidiary: 삼성바이오에피스(주)BYOOVIZ2021-09-17
    FDA drug approval · BLABLA761202
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Onbevzi concentrate for solution for infusion2021-03-11
    Drug · Prescription · Approval202102237
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Samfenet 440 mg powder for concentrate for solution for infusion2020-10-14
    Drug · Prescription · Approval202007039
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Adalloce 40 mg solution for injection in pre-filled penRevoked2020-07-03
    Drug · Prescription · Approval202004865
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Etoloce 50 mg solution for injection in pre-filled pen2019-08-19
    Drug · Prescription · Approval201905857
  • FDA drugSubsidiary: 삼성바이오에피스(주)HADLIMA2019-07-23
    FDA drug approval · BLABLA761059
  • FDA drugSubsidiary: 삼성바이오에피스(주)ETICOVO2019-04-25
    FDA drug approval · BLABLA761066
  • FDA drugSubsidiary: 삼성바이오에피스(주)ONTRUZANT2019-01-18
    FDA drug approval · BLABLA761100
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Samfenet 150 mg powder for concentrate for solution for infusion2017-11-08
    Drug · Prescription · Approval201707851
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Adalloce 40 mg solution for injection in pre-filled syringeRevoked2017-09-20
    Drug · Prescription · Approval201707153
  • FDA drugSubsidiary: 삼성바이오에피스(주)RENFLEXIS2017-04-21
    FDA drug approval · BLABLA761054
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Remaloce 100 mg powder for concentrate for solution for infusion2015-12-04
    Drug · Prescription · Approval201508122
  • MFDS drugSubsidiary: 삼성바이오에피스(주)Etoloce 50 mg solution for injection in pre-filled syringe2015-09-07
    Drug · Prescription · Approval201506388

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 23 more trials

R&D and key agreements

Source: DART corporate disclosure

Nectin-4 ADC · 임상 1상 IND 승인 · Co-developed with Intocell; Phase 1 IND approved by the US FDA in December 2025

EGFR-HER3 ADC · 전임상 · Co-development agreement with China's Phrontline Biopharma; in preclinical stage

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 109 more publications

Patents

KIPRIS · applicant-matched
Show 25 more patents

AI reads

MAA server logs · IP-verified
98
Times AI engines pulled SAMSUNG EPIS HOLDINGS Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

95
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

16
live 0
Last 7 days
67
live 2
Last 30 days
98
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot83
  • PerplexityPerplexityBot7
  • GoogleGoogleOther2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Sep 22, 2026 · 5 AI engines · last read Nov 21, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

4 requests excluded as unverified.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SAMSUNG EPIS HOLDINGS Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

Celemics, Inc.100

Founded in 2010 and listed on KOSDAQ in 2020, Celemics is an NGS-based genomic analysis technology platform company that manufactures and sells Target Capture Kits and the BTSeq next-generation sequencing solution.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

HANDOK Inc.95

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

SAMSUNG BIOLOGICS CO.,LTD.95

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

AHN-GOOK PHARMACEUTICAL Co., Ltd.95

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.95

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

GENOLUTION INC.95

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

HL GENOMICS Co., Ltd.95

Founded in 2000 and listed on KOSDAQ in 2026, HL Genomics manufactures synthetic active pharmaceutical ingredients (APIs).

Daesung Microbiological Labs. Co. Ltd95

KOSDAQ-listed animal pharmaceutical company producing over 150 veterinary products including vaccines and antibiotics.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-11-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition